Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.560
-0.090 (-5.45%)
At close: Nov 20, 2024, 4:00 PM
1.600
+0.040 (2.56%)
Pre-market: Nov 21, 2024, 7:00 AM EST

Company Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.

It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.
Cardiol Therapeutics logo
Country Canada
Founded 2017
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 6
CEO David Elsley

Contact Details

Address:
2265 Upper Middle Road East, Suite 602
Oakville, ON L6H 0G5
Canada
Phone 289-910-0850
Website cardiolrx.com

Stock Details

Ticker Symbol CRDL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency CAD
CIK Code 0001702123
CUSIP Number 14161Y200
ISIN Number CA14161Y2006
SIC Code 2836

Key Executives

Name Position
David G. Elsley MBA President, Chief Executive Officer and Director
Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA Chief Financial Officer, Corporate Secretary and Director
Bernard Lim B.Sc. Chief Operating Officer
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer and Head of Research & Development
Trevor Burns Investor Relations
John A. Geddes BSCPT, MBA Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Nov 18, 2024 6-K Report of foreign issuer
Nov 14, 2024 6-K Report of foreign issuer
Nov 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 6-K Report of foreign issuer
Oct 11, 2024 6-K Report of foreign issuer
Oct 10, 2024 6-K Report of foreign issuer
Oct 9, 2024 SUPPL Filing
Oct 9, 2024 6-K Report of foreign issuer
Oct 8, 2024 6-K Report of foreign issuer
Oct 8, 2024 SUPPL Filing